Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Relay Therapeutics, Inc. (RLAY)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Their company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. These insights may enable them to more effectively drug protein targets that previously have been intractable (i.e. inadequately drugged or undruggable). They believe they have a differentiated approach to drug these protein targets based on their motion, which enables them to select and advance unique product candidates. They built their Dynamo platform to integrate an array of leading edge experimental and computational approaches, which allows them to apply their understanding of protein structure and motion to drug discovery. They initiated a Phase 1 clinical trial for lead candidate RLY-1971, their inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), in patients with advanced solid tumors in the first quarter of 2020. They have completed Investigational New Drug, or IND, enabling activities for RLY-4008, their inhibitor of fibroblast growth factor receptor 2 (FGFR2) and expect to initiate a Phase 1 clinical trial for RLY-4008 in patients with advanced solid tumors having oncogenic FGFR2 alterations in the second half of 2020.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Sanjiv K. Patel Tom Catinazzo
Employees Founded
122 2015

Contacts

Address: 399 Binney Street, 2nd Floor, Cambridge, MA 02139, US

Telephone: (617) 370-8837

Web page: http://www.relaytx.com

IPO information

Expected Date 7/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $1737.5
Revenues (MM) $0
Net Income (Loss) (MM) $-86.0

Voting

What do you think will happen with the RLAY share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 14.7
Shares Revised (MM) 20
Expected offer amount (MM) $249.9
Realized offer amount(MM) $400
Underwriters
JP Morgan/ Goldman Sachs/ Cowen/ Guggenheim Securities
CO-Managers
-

Sector: Healthcare

Tweets about $RLAY

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats